2024-10-09 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes a wide range of innovative therapies.

**1. Performance Analysis:**

* **Cumulative Return:** 152.53%
* **S&P 500 (VOO) Cumulative Return:** 133.14%
* **Outperformance:** 19.39% 
* **Relative Outperformance:** 60.63% (This means AbbVie has outperformed the S&P 500 by a larger margin than 60.63% of its historical performance range)

**2. Recent Price Action:**

* **Closing Price:** 194.29
* **5-day Moving Average:** 196.2
* **20-day Moving Average:** 194.72
* **60-day Moving Average:** 189.8

**3. Technical Indicators:**

* **RSI:** 45.85 (Indicates a neutral market sentiment, neither overbought nor oversold)
* **PPO:** -0.06 (Suggests a slight downward trend)
* **Delta_Previous_Relative_Divergence:** -11.18 (Shows a recent short-term downtrend)
* **Expected Return:** 0.99% (Represents the potential for an additional 0.99% return over the next 5 years compared to the S&P 500)

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

The latest earnings report (2024-07-25) shows that AbbVie surpassed analysts' expectations, with EPS of 2.65 compared to an estimated 2.57. This positive earnings surprise may indicate strong underlying business performance. However, it's important to note that past performance is not necessarily indicative of future results.

**5. News and Recent Issues:**

* **Recent Market Outlook:** AbbVie is currently facing some challenges in its Humira biosimilar competition, which may impact near-term revenue growth. However, analysts remain optimistic about the company's long-term prospects due to its robust pipeline of innovative therapies and potential for future growth in areas like immunology and oncology.
* **Analyst Opinions and Performance Highlights:** According to FINBOLD, AbbVie is currently rated as a "Strong Buy" with a consensus price target of $196.60. The majority of analysts believe AbbVie is a good investment opportunity, citing its strong brand recognition, diversified product portfolio, and potential for future growth.

**6. Comprehensive Analysis:**

AbbVie has consistently outperformed the S&P 500, demonstrating its strong track record. The recent earnings beat and positive analyst sentiment suggest a promising outlook. However, the short-term downtrend in technical indicators and the potential impact of Humira biosimilars warrant monitoring. Despite these challenges, AbbVie's robust pipeline and strong fundamentals support a potentially favorable investment case for long-term investors.

**7. Conclusion:**

Overall, AbbVie presents a compelling investment opportunity, with a history of strong outperformance, a robust pipeline of innovative therapies, and favorable analyst sentiment. While near-term headwinds exist, AbbVie's long-term growth prospects remain positive, making it a potentially attractive investment for long-term investors seeking exposure to the biopharmaceutical industry.